Front | Back |
Size criteria for T2 non-melanoma skin cancer
|
More than 2cm but not more than 5cm
|
5 year local control for RT for T3 SCC non melanoma skin cancer
|
50%
|
Post-op indications for non-melanoma skin cancer
|
Positive margins, PNI of named nerve, larger than 3cm primary, extensive skeletal muscle, bone, or cartilage invasion, SCC of the parotid
|
Contraindications for non-melanoma skin cancer XRT
|
Age
|
Margins for nonmelanoma skin cancer 2cm sized primaries?
|
0.5-1.0cm and 1.5 to 2.0cm
|
Dose for 2cm, and >2cm with cartilage involvement of nonmelanoma skin cancer
|
45-50gGy, 50-55Gy, 60-66Gy
|
Distant met % in Merkel Cell Carcinoma
|
50-60%
|
Dose for Merkel Cell Carcinoma - N0, microscopic disease, microscopic with +margins, macroscopic
|
N0 45-50Gy, microscopic 45-50Gy, positive margin microscopic 55-60Gy, macroscopic 55-60Gy
|
3yr OS for Merkel Cell for stage I, II, III
|
I - 70-80%, II - 50-60%, III - 30%
|
Most important prognostic factor for melanoma recurrence and survival
|
SLN status
|
What is the stage of a 2.5 mm thick melanoma with ulceration
|
T3b
|
What is stage of 1.5mm thick melanoma with ulceration and satellite metastasis without positive node
|
T2bN2c, stage grouping IIIB
|
What are indications for adjuvant XRT with melanoma
|
Multiple LN, matted LN, or ECE
|
What was the outcome of the melanoma RTOG 8305 trial of 32Gy in 4 fx vs 50Gy in 20 fx.
|
No difference
|
What is the melanoma follow up for stage IB-III
|
Q3-6mo for 3 years, then q4-12 months for 2 years, then annually
|